Kindred Biosciences (KIN) Tops Q3 EPS by 5c

Kindred Biosciences (NASDAQ: KIN) reported Q3 EPS of ($0.29), $0.05 better than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Kindred Biosciences (KIN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c